Printer Friendly

IVAX' SUBSIDIARY RECEIVES APPROVAL TO SELL SODIUM CROMOGLYCATE METERED DOSE INHALER IN THE UNITED KINGDOM

 IVAX' SUBSIDIARY RECEIVES APPROVAL TO SELL
 SODIUM CROMOGLYCATE METERED DOSE INHALER IN THE UNITED KINGDOM
 MIAMI, Feb. 21 /PRNewswire/ -- IVAX Corporation (AMEX: IVX) announced today that its wholly owned subsidiary Norton Healthcare Limited has received approval from the United Kingdom Department of Health to sell metered dose inhaler versions of sodium cromoglycate (1 mg. and 5 mg.). The products will be marketed in the United Kingdom by Baker Norton Pharmaceuticals Ltd., a division of Norton Healthcare, under the name Cromogen(TM). The product is a prophylactic agent indicated in the management of patients with bronchial asthma and is currently sold under the brand name Intal(R) by Fisons Pharmaceuticals. Intal(R) is a registered trademark of Fisons plc.
 Isaac Kaye, the Deputy Chief Executive Officer of IVAX and the chief executive officer of Norton Healthcare said, "We are very pleased to receive a license in the United Kingdom for this product. The approval of the sodium cromoglycate inhaler will further enhance the company's respiratory product line."
 IVAX Corporation is a holding company with subsidiaries involved in specialty chemicals, pharmaceuticals and medical diagnostics. IVAX' principal subsidiaries include Baker Cummins Pharmaceuticals, Inc., a developer and marketer of unique brand name pharmaceuticals; Norton Healthcare Limited, a leading manufacturer and marketer of off-patent pharmaceuticals in the United Kingdom, Ireland and other countries; Goldline Laboratories, Inc., a national marketer of off-patent prescription and over the counter pharmaceuticals in the United States; Best Generics, Inc., a national distributor of off-patent pharmaceuticals in the United States; Baker Cummins Dermatologicals, Inc., a dermatological products company; Diamedix Corporation, a medical diagnostics company; Delta Biologicals S.r.l., a marketer of medical diagnostic tests and instruments in Italy; and IVAX Industries, Inc., a chemical specialties business.
 -0- 2/21/92
 /CONTACT: Richard C. Pfenniger Jr., senior vice president of legal affairs of IVAX Corporation, 305-590-2309/
 (IVX) CO: IVAX Corporation; Norton Healthcare Limited ST: Florida IN: MTC SU:


AW-JJ -- FL006 -- 1301 02/21/92 09:53 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 21, 1992
Words:326
Previous Article:/C O R R E C T I O N -- LUFKIN INDUSTRIES INC. ANNOUNCES 1991 EARNINGS AND DIVIDENDS FOR FIRST QUARTER 1992
Next Article:ITAR-TASS INITIATES INTELSAT SATELLITE NETWORK
Topics:


Related Articles
IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR TOLMETIN
IVAX ANNOUNCES JOINT DEVELOPMENT AGREEMENT WITH GLAXO
IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR VERAPAMIL
IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR VERAPAMIL
IVAX COMMENCES DISTRIBUTION OF VERAPAMIL
IVAX SUBSIDIARY GRANTED APPROVAL TO MARKET BECLOMETHASONE MET RED DOSE INHALER IN U.K.
IVAX CORPORATION ACQUIRES POLISH PHARMACEUTICAL DISTRIBUTOR
IVAX CORPORATION RECEIVES TENTATIVE FDA APPROVAL FOR GENERIC TERFENADINE
IVAX ANNOUNCES RECORD ANNUAL EARNINGS
IVAX Prevails Over Bristol-Myers Squibb And 3M Company In U.K. Patent Suits

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters